Prilosec Long-Term Efficacy Acknowledged By FDA Advisory Committees
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca/Procter & Gamble's decision to seek a 20 mg OTC dose for Prilosec was endorsed by FDA advisory committee members at a meeting in Gaithers-burg, Md Oct. 20.
You may also be interested in...
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")
Prilosec 1 Switch For Heartburn Prevention, 14-Day Use To Be Considered
OTC omeprazole will return for a second FDA advisory committee review June 21 with a revised indication and recommended duration of use
OTC Prilosec For Chronic Use Needs Explicit Labeling, NDAC, GDAC Advise
Chronic use of OTC Prilosec (omeprazole) may benefit patients with gastroesophageal reflux disease provided labeling explicitly lists appropriate warnings, advisory committee members concluded at a switch review for the heartburn drug.